The University of Calgary (UCalgary) intends to award a service contract to Peters:Gibson Strategies for Commercialization Consulting Services. The UCalgary Riddell Centre for Cancer Immunotherapy aims to transform their discoveries and innovations into therapeutic products that maximize patient impact. Achieving this requires a commercialization framework combining deep scientific and product development expertise in the immunotherapy field, with sophisticated local, provincial, national and international knowledge of funding, company building and stakeholder engagement models. Building this framework requires a deep understanding of the science and technologies under exploration across the Centre’s teams, specifically in areas such as adoptive cell therapy and other immune-stimulating treatments. It is the Centre’s understanding that only Peters:Gibson Strategies possesses the necessary expertise and can meet all the requirements.
It is UCalgary’s intention to establish a one (1) year agreement with renewal options with Peter:Gibson Strategies.
